The causal relation between human papillomavirus and cervical cancer

Journal of Clinical Pathology

Volumn 55, Issue 4, 2002, Pages 244-265

  Bosch, F X ^a   Lorincz, A ^b   Munoz N ^c   Meijer, C J L M ^d   Shah, K V ^e  

^a HOSPITAL CLÍNIC   (Spain)

^b Digene Corporation   (United States)

^c INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ORAL CONTRACEPTIVE AGENT; VIRUS DNA;

CANCER MODEL; CANCER RESEARCH; DISEASE ASSOCIATION; HUMAN; PARITY; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; RISK FACTOR; SCREENING; SENSITIVITY AND SPECIFICITY; SMOKING; UTERINE CERVIX CANCER; VACCINATION; VIRUS CARCINOGENESIS; VIRUS INFECTION; VIRUS TYPING; WART VIRUS;

EID: 0036221471     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.55.4.244     Document Type: Review

References (276)

1. The sexually transmitted disease model for cervical cancer: Incoherent epidemiologic findings and the role of misclassification of human papillomavirus infection
2. Risk factors for cervical cancer in Colombia and Spain
3. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia
4. Human papillomaviruses and cervical cancer in Bangkok. I. Risk factors for invasive cervical carcinomas with human papillomavirus types 16 and 18 DNA
5. On the methodology of investigations of etiologic factors in chronic disease - Some comments
6. On the methodology of investigations of etiologic factors in chronic disease - Further comments
7. The environment and disease: Association or causation?
8. Concepts of causes
9. Human papillomaviruses
10. Causal and preventive inference
11. Causation and disease: The Henle-Koch postulates revisited
12. Causes
13. Papillomaviruses
14. Papillomavirus causing cancer: Evasion from host-cell control in early events in carcinogenesis
15. Reviews and commentary. Causes
16. Causal inference in epidemiology
17. Rapid human papillomavirus detection in cervical scrapes by combined general primer mediated and type-specific polymerase chain reaction
18. The use of general primers GP5 and GP6 elongated at their 3′ ends with adjacent highly conserved sequences improves human papillomavirus detection by polymerase chain reaction
19. Papillomavirus research update: Highlights of the Barcelona HPV 2000 international papillomavirus conference
20. The causal link between human papillomavirus and invasive cervical cancer: A population-based case-control study in Colombia and Spain
21. Human papillomavirus and invasive cervical cancer in Brazil
22. The viral origin of cervical cancer in Rabat, Morocco
23. Human papillomavirus infection and invasive cervical cancer in Paraguay
24. Causes of cervical cancer in the Philippines: A case-control study
25. Risk factors for cervical cancer in Thailand: A case control study
26. HPV types and cofactors causing cervical cancer in Peru
27. Natural history of cervical human papillomavirus infection in young women: A longitudinal cohort study
28. A multinational case-control study on the risk of cervical cancer linked to 25 HPV types: Which are the high-risk types?
29. HPV and cervical adenocarcinoma: An IARC based multicentric case-control study
30. Prevalence of human papillomavirus cervical cancer: A worldwide perspective
31. Human papillomavirus genotypes in rural Mozambique
32. HPV International prevalence surveys in general populations
33. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica
34. Human papillomaviruses and cervical cancer in Bangkok. II. Risk factors for in situ and invasive squamous cell cervical carcinomas
35. Human papillomavirus in cervical intraepithelial neoplasia grade II-III: A population-based case-control study
36. Human papillomavirus - The most significant risk determinant of cervical intraepithelial neoplasia
37. Infección por los virus del papiloma humano y de la inmunodeficiencia humana como factores de riesgo para el cáncer de cuello uterino en mujeres reclusas
38. Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women
39. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan
40. Hepatitis B and viruses in the etiology of hepatocellular carcinoma; a study in Greece using third-generation assays
41. Hepatitis B and C virus infection, alcohol drinking, and hepatocellular carcinoma: A case-control in study Italy
42. Smoking, smoking cessation, and lung cancer in the UK since 1950: Combination of national statistics with two case-control studies
43. Hepatitis B vaccination and reduced risk of primary liver cancer among male adults: A cohort study in Korea
44. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children
45. Risk factors for progression of cervical intraepithelial neoplasm grade III to invasive cervical cancer
46. Correlation between the progression of cervical dysplasia and the prevalence of human papillomavirus
47. High rate of concurrent genital infections with human cytomegalovirus and human papillomaviruses in cervical cancer patients
48. Human papillomavirus type 18 associates with more advanced cervical neoplasia than human papillomavirus type 16
49. A high frequency of human papillomavirus DNA sequences in cervical carcinomas of Indian women as revealed by Southern blot hybridization and polymerase chain reaction
50. Human papillomavirus (HPV) infection, HIV infection and cervical cancer in Tanzania, East Africa
51. HPV and cervical neoplasia: Review of case-control and cohort studies
52. Human papillomavirus types 16 and 33, herpes simplex virus type 2 and other risk factors for cervical cancer in Sichuan Province, China
53. Demonstration of multiple HPV types in normal cervix and in cervical squamous cell carcinoma using the polymerase chain reaction on paraffin wax embedded material
54. Detection of human papillomaviruses (HPV-16, 18) in cervical smears by in situ hybridization
55. Human papillomavirus infection of the cervix: Relative risk associations of 15 common anogenital types
56. Risk factors for cervical cancer in a black, elderly population: Preliminary findings
57. Biologic characteristics of specific human papillomavirus types predicted from morphology of cervical lesions
58. Is human papillomavirus associated with cervical neoplasia in elderly?
59. TM) method
60. Epidemiologic background and changes in patients infected with human papilloma virus
61. The association between cervical carcinoma and human papilloma virus (HPV) in Xiangyuan county
62. A research for the relationship between human papillomavirus and human uterine cervical carcinoma. I. The identification of viral genome and subgenomic consequences in biopsies of Chinese patients
63. Detection of human papillomavirus (HPV) in genital warts and carcinomas by DNA in situ hybridization in Chinese patients
64. A study on the relationship between human papilloma virus (HPV) and cervical cancer
65. Detection of human papillomavirus types 6/11, 16 and 18 in exfoliated cells from the uterine cervices of japanese women with and without lesions
66. Human papillomavirus infection of morphologically normal cervical epithelium ad acent to squamous dysplasia and invasive carcinoma
67. Detection of human papillomavirus deoxyribonucleic acid in the female genital tract
68. Human papillomavirus infection and cervical cancer in Latin America
69. Reproductive and sexual risk factors and human papilloma virus infection in cervical cancer among Hong Kong
70. Papillomavirus and cervical cancer; a clinical and laboratory study
71. Adenocarcinoma of the cervix associated with human papillomavirus
72. Pfister human papillomavirus DNA in normal, metaplastic, preneoplastic and epithelia of the cervix uteri
73. Presence and expression of human papillomavirus types 16 and 18 DNA sequences in cervical carcinomas
74. A distinct difference in the prevalence of papillomavirus infection in cytologically normal and neoplastic cells of the uterine cervix
75. ECDNA sequences of human papillomavirus types 11, 16 or 18 in invasive cervical carcinoma of Western Australian women
76. Relation between human papillomavirus (HPV) and cancer of uterine cervix
77. Oncogenic association of specific human papillomavirus types with cervical neoplasia
78. Multifocal squamous neoplasia of the female genital tract: Significance of human papillomavirus infection of the vagina after hysterectomy
79. HPV 16 DNA in normal and malignant cervical epithelium: Implications for the aetiology and behaviour of cervical neoplasia
80. Prevalence of human papillomavirus type 16 DNA sequences in cervical intraepithelial neoplasia and invasive carcinoma of the cervix
81. Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: A nested case-control study
82. A prospective study showing long-term infection with human papillomavirus 16 before the development of cervical carcinoma in situ
83. Association between smoking and adenocarcinomas and squamous cell carcinomas of the uterine cervix (United States)
84. Multifocal vulvar intraepithelial neoplasia grade III and multicentric lower genital tract neoplasia is associated with transcriptionally active human papillomavirus
85. Human papillomavirus DNA in multicentric vulvar intraepithelial neoplasia
86. Squamous cell carcinoma of the vulva in brazil: Prognostic importance of host and viral variables
87. Association of papillomavirus with cancers of the head and neck
88. Prevalence and expression of human papillomavirus in tonsillar carcinomas, indicating a possible viral etiology
89. Age-dependence of human papillomavirus DNA presence in oral squamous cell carcinomas
90. Aetiological parallel between tonsillar and anogenital squamous-cell carcinomas
91. Human papillomavirus infection and non-melanoma skin cancer in immunosuppressed and immunocompetent individuals
92. Review of the aetiology of squamous cell carcinoma of the conjunctiva
93. Genomic variation of human papillomavirus type 16 and risk for high grade cervical intraepithelial neoplasia
94. Molecular variants of human papillomavirus types 16 and 18 preferentially associated with cervical neoplasia
95. Human papillomavirus type 16 variants and risk of cervical cancer
96. HPV infections in other sites and lesions
97. Epidemiology of HPV infection among Mexican women with normal cervical cytology
98. Prevalence of HPV in cytomorphologically normal cervical smears, as determined by the polymerase chain reaction, is age-dependent
99. Determinants of genital human papillomavirus infection in low-risk women in Portland, Oregon
100. Importance of human papillomavirus endemicity in the incidence of cervical cancer: An extension of the hypothesis on sexual behavior
101. Determinants for genital human papillomavirus (HPV) infection in 1000 randomly chosen young Danish women with normal Pap smear: Are there different risk profiles for oncogenic and nononcogenic HPV types?
102. Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: The age-related patterns for high-risk and low-risk types
103. Screening for high-grade cervical intra-epithelial neoplasia and cancer by testing for high-risk HPV, routine cytology or colposcopy
104. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer
105. Natural history of cervicovaginal papillomavirus infection in young women
106. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection
107. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia
108. The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: Natural history up to 36 months
109. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: A prospective study
110. PCR-based high-risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorphologically normal cervical smears
111. PCR based high risk HPV testing is superior to neural network based screening for predicting incident CIN III in women with normal cytology and borderline changes
112. HPV presence precedes abnormal cytology in women developing cervical cancer and signals false negative smears
113. Cytological regression and clearance of high-risk human papillomavirus in women with abnormal cervical smear
114. Identifying women with cervical neoplasia: Using human papillomavirus DNA testing for equivocal Papanicolaou results
115. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia
116. High-risk HPV testing in women with borderline and mild dyskaryosis: Long-term follow-up data and clinical relevance
117. Addition of high-risk HPV testing improves the current guidelines on follow-up after treatment for cervical intraepithelial neoplasia
118. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer
119. Prospective seroepidemiologic study of human papillomavirus infection as a risk factor for invasive cervical cancer
120. Progressive potential of mild cervical atypia; prospective cytological, colposcopic, and virological study
121. Human papillomavirus type 16 DNA in cervical smears as predictor of high-grade cervical cancer
122. Type-specific human papillomavirus DNA in abnormal smears as a predictor of high-grade cervical intraepithelial neoplasia
123. Human papillomavirus testing in primary cervical screening
124. A systematic review of the role of human papillomavirus (HPV) testing within a cervical screening programme: Summary and conclusions
125. Human papillomavirus testing for primary screening of cervical cancer precursors
126. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: Baseline results from a randomized trial
127. Hybrid capture II-based human papillomavirus detection, a sensitive test to detect in routine high-grade cervical lesions: A preliminary study on 1518 women
128. HPV DNA testing in cervical cancer screening
129. HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer
130. Determinants of genital human papillomavirus infection in low-risk women in Washington, DC
131. Determinants of genital human papillomavirus infection among cytologically normal women attending the University of New Mexico student health center
132. Transmission of cervical human papillomavirus infection by sexual activity: Differences between low- and high-risk oncogenic types
133. Risk factors for HPV DNA detection in middle-aged women
134. Correlates of the spread of human papillomavirus infection
135. A cumulative case-control study of risk factor profiles for oncogenic and non-oncogenic cervical human papillomavirus infections
136. High-risk human papillomavirus is sexually transmitted: Evidence from a follow-up study of virgins starting sexual activity (intercourse)
137. High prevalence of papillomavirus-associated penile intraepithelial neoplasia in sexual partners of women with cervical intraepithelial neoplasia
138. Case-control study of risk factors for cervical neoplasia in Denmark. I: Role of the "male factor" in women with one lifetime sexual partner
139. Prevalence of human papillomavirus infection in men: Comparison of the partners of infected and uninfected women
140. Male sexual behavior and human papillomavirus DNA: Key risk factors for cervical cancer in Spain
141. Prevalence of penile human papillomavirus DNA in husbands of women with and without cervical neoplasia: A study in Spain and Colombia
142. Prostitution, HIV, and cervical neoplasia: A survey in Spain and Colombia
143. Human papillomaviruses and cervical cancer in Bangkok. III. The role of husbands and commercial sex workers
144. Human papillomavirus: A highly prevalent sexually transmitted disease agent among female sex workers from Mexico City
145. Male circumcision, penile human papillomavirus (HPV) infection and cervical cancer
146. Fatti statistici relativi alle malattie cancerose
147. Cancer of the cervix: A sexually transmitted infection?
148. Importance of the male factor in cancer of the cervix
149. New epidemiology of human papillomavirus infection and cervical neoplasia
150. Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: A nested case-control study
151. Human papillomavirus 16 load in normal and abnormal cervical scrapes: An indicator of CIN II/III and viral clearance
152. Rapid real time PCR to distinguish between high risk human papillomavirus types 16 and 18
153. MHC expression in the natural history of cervical cancer
154. The molecular genetics of cervical carcinoma
155. Human papillomavirus oncogenesis
156. Immortalization of human foreskin keratinocytes by various human papillomavirus DNAs corresponds to their association with cervical carcinoma
157. In vitro systems for the study and propagation of human papillomaviruses
158. Transition of human papillomavirus type 16 and 18 transfected human foreskin keratinocytes towards immortality: Activation of telomerase and allele losses at 3p, 10p, 11q and/or 18q
159. Human papillomavirus type 16 and 18 gene expression in cervical neoplasias
160. Human papillomavirus deoxyribonucleic acid in cervical carcinoma from primary and metastatic sites
161. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells
162. Human papillomavirus type 16 (HPV 16) gene expression and DNA replication in cervical neoplasia: Analysis by in situ hybridization
163. The physical state of human papillomavirus type 16 DNA in benign and malignant genital tumours
164. Analysis of the physical state of different human papillomavirus DNAs in intraepithelial and invasive cervical neoplasm
165. Suppression of malignancy in human cells
166. Introduction of human chromosome 11 via microcell transfer controls tumorigenic expression of HeLa cells
167. Normal human chromosome 11 suppresses tumorigenicity of human cervical tumor cell line SiHa
168. Microcell-mediated transfer of chromosome 4 into HeLa cells suppresses telomerase activity
169. Telomerase suppression by chromosome 6 in a human papillomavirus type 16-immortalized keratinocyte cell line and in a cervical cancer cell line
170. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product
171. Human papillomaviruses
172. Association of human papillomavirus types 16 and 18 E6 proteins with p53
173. Differentiation-dependent up-regulation of the human papillomavirus E7 gene reactivates cellular DNA replication in suprabasal differentiated keratinocytes
174. Post-transcriptional induction of p21cip1 protein by human papillomavirus E7 inhibits unscheduled DNA synthesis reactivated in differentiated keratinocytes
175. Post-transcriptional induction of p21cip1 protein in condylomata and dysplasias is inversely related to human papillomavirus activities
176. Viral E6-E7 transcription in the basal layer of organotypic cultures without apparent p21cip1 protein precedes immortalization of HPV 16 and HPV 18 transfected human keratinocytes
177. Human papillomaviruses and cervical neoplasia: A model for carcinogenesis
178. Immune activation in cervical neoplasia: Cross-sectional association between plasma soluble interleukin 2 receptor levels and disease
179. Interleukin 2 production in vitro by peripheral lymphocytes in response to human papillomavirus-derived peptides: Correlation with cervical pathology
180. Papillomavirus DNA replication
181. Production of human papillomavirus and modulation of the infectious program in epithelial raft cultures
182. Evidence for a switch in the mode of human papillomavirus type 16 DNA replication during the viral life cycle
183. Interactions of HPV E6 and E7 oncoproteins with tumour suppressor gene products
184. The genetic program of genital human papillomaviruses in infection and cancer
185. Roots and perspectives of contemporary papillomavirus research
186. CDK2 and cyclin A
187. Induction of proliferating cell nuclear antigen in differentiated keratinocytes of human papillomavirus-infected lesions
188. Differentiation-linked human papillomavirus types 6 and 11 transcription in genital condylomata revealed by in situ hybridization with message-specific RNA probes
189. Human papillomavirus type 18 is associated with less apoptosis in fibroblast tumours than human papillomavirus type 16
190. 1 growth arrest pathway in cells expressing the human papillomavirus type 16 E7 oncoprotein
191. Human papillomavirus type 16 alters human epithelial cell differentiation in vitro
192. Telomerase and the HPV oncogenes: More than a terminal relationship
193. Integration of human papillomavirus type 16 into the human genome correlates with a selective growth advantage of cells
194. Papillomavirus infections - A major cause of human cancers
195. A novel C/EBP beta-YY1 complex controls the cell-type-specific activity of the human papillomavirus type 18 upstream regulatory region
196. Prevalence of deletions of YY1-binding sites in episomal HPV 16 DNA from cervical cancers
197. The E6/E7 promoter of extrachromosomal HPV 16 DNA in cervical cancers escapes from cellular repression by mutation of target sequences for YY1
198. Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage
199. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines
200. Kohn EC The microenvironment of the tumour-host interface
201. Towards vaccines against papillomavirus
202. Taxonomic classification of papillomavirus
203. Association between poor prognosis in early-stage invasive cervical carcinomas and non-detection of HPV DNA
204. Human papillomavirus DNA and antibodies to human papillomaviruses 16 E2, L2, and E7 peptides as predictors of survival in patients with squamous cell cervical cancer
205. Epidemiological characteristics of women with high grade CIN who do and do not have human papillomavirus
206. Epidemiological evidence of cervical intraepithelial neoplasia without the presence of human papillomavirus
207. Does human papillomavirus cause cervical cancer? The state of the epidemioiogical evidence
208. Test reliability is critically important to molecular epidemiology: An example from studies of human papillomavirus infection and cervical neoplasia
209. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide
210. Sexual behaviour and smoking as determinants of cervical HPV infection and of CIN 3 among those infected: A case-control study nested within the Manchester cohort
211. Sexually transmitted agents and cervical neoplasia in Colombia and Spain
212. Risk factors of invasive cervical cancer in Mall
213. Oral contraceptives and cervical cancer: Pooled analysis of the IARC multicentric case-control study
214. Different risk factor patterns for high-grade and low-grade intraepithelial lesions on the cervix among HPV-positive and HPV-negative young women
215. Oral contraceptives as risk factors for cervical adenocarcinomas and squamous cell carcinomas
216. The influence of reproductive and menstrual factors on cervical cancer in HPV-positive women
217. HPV co-factors related to the development of cervical cancer: Results from a population-based study in Costa Rica
218. Human papillomavirus, herpes simplex virus and cervical cancer incidence in Greenland and Denmark. A population-based cross-sectional study
219. Co-factors related to the causal relationship between human papillomavirus and invasive cervical cancer in Honduras
220. Smoking and cancer of the uterine cervix: Hypothesis
221. Smoking and cervical neoplasia: A review of the evidence
222. Risk factors for cervical neoplasia in Denmark
223. The E antigen and vertical transmission of hepatitis B surface antigen
224. Age and sex-related study of hepatitis B virus chronic carrier state in infants from an endemic area (Senegal)
225. Epstein-Barr virus
226. Evidence for Chlamydia trachomatis as an HPV cofactor in the etiology of invasive cervical cancer in Brazil and the Philippines
227. An association of cervical inflammation with high-grade cervical neoplasio in women infected with oncogenic human papillomavirus (HPV)
228. Social differences in sexual behaviour and cervical cancer
229. Nutrition and cervical neoplasia
230. Role of p53 polymorphism in the development of human papillomavirus-associated cancer
231. p53 polymorphism in codon 72 and risk of HPV-induced cervical cancer: Effect of interbboratory variation
232. The p53 Arg72Pro polymorphism, human papillomavirus, and invasive squamous cell cervical cancer
233. Lack of association between p53 codon-72 polymorphism and squamous intraepithelial lesions in women with, or at risk for, human immunodeficiency virus and/or human papillomavirus infections
234. p53 codon 72 polymorphisms and various human papillomavirus 16 E6 genotypes are risk factors for cervical cancer development
235. Chlamydia trachomatis infection as a risk factor for invasive cervical cancer
236. Development of HPV induced cervical intraepithelial neoplasias: Infection with Chlamdya trachomatis as a possible cofactor
237. Epidemiologic correlates of cervical neoplasia and risk of human papillomavirus infection in asymptomatic women in Brazil
238. Comparison of ViraPap, Southern hybridization, and polymerase chain reaction methods for human papillomavirus identification in an epidemiological investigation of cervical cancer
239. Cervical carcinoma and human papillomavirus: On the road to preventing a major human cancer
240. Re: Cervical carcinoma and human papillomavirus: On the road to preventing a major human cancer
241. Detection of human papilloma virus in cervical scrapes by the polymerase chain reaction in relation to cytology: Possible implications for cervical cancer screening
242. HPV testing in primary screening of older women
243. Nonisotopic detection and typing of human papillamovirus DNA in genital samples by the line blot assay
244. Prevalence and predictors of human papillomavirus infection in women in Ontario, Canada
245. Cervical cytology after 2000: Where to go?
246. Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: Baseline data from a randomized trial
247. Emerging technologies and cervical cancer
248. Human papillomavirus screening and cervical cancer prevention
249. Inverse relationship between the expression of the human papillomavirus type 16 transcription factor E2 and virus DNA copy number during the progression of cervical intraepithelial neoplasia
250. Comparison of human papillomavirus types 16, 18 and 6 capsid antibody responses following incident infection
251. Cervical cancer: Epidemiology, prevention and the role of human papillomavirus infection
252. Human papillomavirus infection, risk for subsequent development of cervical neoplasia and associated population attributable fraction
253. Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma
254. The role of human papillomavirus in cervical adenocarcinoma carcinogenesis
255. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: A study of 7932 women
256. Policy analysis of cervical cancer screening strategies in low-resource settings. Clinical benefits and cost-effectiveness
257. Human papillomavirus and prognosis of invasive cervical cancer: A population-based study
258. A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types
259. Evaluation of self-collected cervicovaginal cell samples for human papillomavirus testing by polymerase chain reaction
260. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine
261. Determinants of genital human papillomavirus detection in a US population
262. From epidemiology to policy: A symposium on the translation of epidemiologic evidence into public health policy
263. Causal inference is not a matter of science
264. Science and policy making